FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
Read original at benzingaStocks · News reference
BTIG Downgrades Insulet to Neutral
BTIG analyst Marie Thibault downgrades Insulet (NASDAQ:PODD) from Buy to Neutral.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 10:05 AM
- Checked
- Aug 6, 2026, 10:05 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers – PODD
Pomerantz LLP filed a class action lawsuit against Insulet Corporation (PODD) for alleged securities fraud. The complaint alleges that Insulet made false statements about its manufacturing controls and failed to disclose defective procedures that created safety risks. Two voluntary medical device corrections were announced in March and May 2026, resulting in significant stock price declines of 6.88% and 5.07% respectively. Investors who purchased Insulet securities between February 21, 2025 and May 26, 2026 can join the class action.
Read original at globenewswire-incInsulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors?
Insulet CEO Ashley McEvoy purchased 1,100 shares worth approximately $162,217 at a weighted average price of $147.47 per share on August 21, 2026, increasing her total beneficial ownership to 23,735 shares valued at $3.52 million. The insider buy comes after the stock declined 55% over the preceding year and is viewed as a bullish signal, suggesting McEvoy's confidence in the company's ability to reverse its bearish trend under her leadership since April 2025.
Read original at the-motley-foolCanaccord Genuity Maintains Buy on Insulet, Lowers Price Target to $179
Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $249 to $179.
Read original at benzinga